JP2005509412A - チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体 - Google Patents

チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体 Download PDF

Info

Publication number
JP2005509412A
JP2005509412A JP2003523491A JP2003523491A JP2005509412A JP 2005509412 A JP2005509412 A JP 2005509412A JP 2003523491 A JP2003523491 A JP 2003523491A JP 2003523491 A JP2003523491 A JP 2003523491A JP 2005509412 A JP2005509412 A JP 2005509412A
Authority
JP
Japan
Prior art keywords
tsh receptor
amino acid
tsh
polypeptide
autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003523491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005509412A5 (https=
Inventor
スミス，バーナード，リース
ファーマニアック，ジャデュガ
サンダーズ，ジェン、フィーナ
Original Assignee
アールエスアール リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0120649A external-priority patent/GB0120649D0/en
Priority claimed from GB0215212A external-priority patent/GB0215212D0/en
Application filed by アールエスアール リミテッド filed Critical アールエスアール リミテッド
Publication of JP2005509412A publication Critical patent/JP2005509412A/ja
Publication of JP2005509412A5 publication Critical patent/JP2005509412A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
JP2003523491A 2001-08-23 2002-08-21 チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体 Pending JP2005509412A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0120649A GB0120649D0 (en) 2001-08-23 2001-08-23 Epitope regions of a thyrotrophin (TSH) receptor and uses thereof
GB0215212A GB0215212D0 (en) 2002-07-01 2002-07-01 Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
PCT/GB2002/003831 WO2003018632A2 (en) 2001-08-23 2002-08-21 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009171358A Division JP5576072B2 (ja) 2001-08-23 2009-07-22 チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体

Publications (2)

Publication Number Publication Date
JP2005509412A true JP2005509412A (ja) 2005-04-14
JP2005509412A5 JP2005509412A5 (https=) 2006-01-05

Family

ID=26246470

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003523491A Pending JP2005509412A (ja) 2001-08-23 2002-08-21 チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体
JP2009171358A Expired - Lifetime JP5576072B2 (ja) 2001-08-23 2009-07-22 チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009171358A Expired - Lifetime JP5576072B2 (ja) 2001-08-23 2009-07-22 チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体

Country Status (6)

Country Link
US (4) US8298769B2 (https=)
EP (3) EP2383291B1 (https=)
JP (2) JP2005509412A (https=)
CN (3) CN103224562B (https=)
ES (3) ES2736165T3 (https=)
WO (1) WO2003018632A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2736165T3 (es) 2001-08-23 2019-12-26 Rsr Ltd Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas
WO2004050708A2 (en) * 2002-11-29 2004-06-17 Rsr Limited Antibody for the thyrotropin receptor and uses thereof
ES2382627T3 (es) 2004-06-29 2012-06-12 B.R.A.H.M.S Gmbh Nuevos anticuerpos monoclonales estimuladores o bloqueadores de la tiroides, secuencias peptídicas que corresponden a sus regiones variables, y sus usos en medicina diagnóstica, preventiva y terapéutica
GB0418181D0 (en) 2004-08-13 2004-09-15 Rsr Ltd Thyrotrophin receptor preparations,thyrotrophin receptor epitopes,antibody and hormone interactions therewith,and uses thereof
EP1951753A2 (en) * 2005-11-21 2008-08-06 Dr. Fenning Biomed GmbH Recombinant polypeptides and methods for detecting and/or quantifying autoantibodies against tsh receptor
JP5165672B2 (ja) * 2006-03-29 2013-03-21 キングス カレッジ ロンドン Ｔｓｈｒに対するアゴニスト抗体
ES2550158T3 (es) * 2007-08-06 2015-11-04 Chugai Seiyaku Kabushiki Kaisha Método para medir la actividad inhibidora sobre la unión ligando-receptor
JP5784504B2 (ja) * 2008-12-24 2015-09-24 アールエスアール リミテッド ヒト抗ｔｓｈｒ抗体
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
ES2996234T3 (en) 2014-12-24 2025-02-12 Worg Pharmaceuticals Zhejiang Co Ltd Composition
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
FI3380620T3 (fi) 2015-11-23 2024-08-01 Novartis Ag Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020092928A1 (en) * 2018-11-02 2020-05-07 The Regents Of The University Of California Compositions and methods for diagnosis of cardiovascular disease
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024046384A1 (zh) * 2022-08-31 2024-03-07 长春金赛药业有限责任公司 结合促甲状腺激素受体的抗体及其用途
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
PE20252789A1 (es) 2023-05-24 2025-12-22 Kumquat Biosciences Inc Compuestos heterociclicos y usos de estos
CN119930815A (zh) * 2023-10-27 2025-05-06 上海交通大学医学院附属第九人民医院 一种全人源tsh受体阻断性单克隆抗体及其制备和应用
CN119086939B (zh) * 2024-10-10 2026-04-07 深圳市新产业生物医学工程股份有限公司 四碘甲状腺素自身抗体作为癌症治疗过程中的甲状腺功能异常标志物的应用
CN119510769B (zh) * 2024-10-10 2026-03-31 深圳市新产业生物医学工程股份有限公司 三碘甲状腺素自身抗体作为癌症治疗过程中的甲状腺功能异常标志物的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244940A (en) 1978-09-05 1981-01-13 Bio-Rad Laboratories, Inc. Single-incubation two-site immunoassay
US4514498A (en) 1982-05-26 1985-04-30 The Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Treponema
US4472508A (en) 1982-12-30 1984-09-18 The Beth Israel Hospital Association Test for detecting and measuring the graves' disease-specific immunoglobulins
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
US4609622A (en) 1983-05-31 1986-09-02 Interthyr Research Foundation Inc. Clinical determination and/or quantification of thyrotropin and a variety of thyroid stimulatory or inhibitory factors performed in vitro with an improved thyroid cell line, FRTL-5
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4661446A (en) 1985-02-19 1987-04-28 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies and method of immunizing therewith
WO1990008528A1 (en) 1989-01-11 1990-08-09 The United States Of America, Represented By The Secretary, United States Department Of Commerce Biologically active synthetic thyrotropin and cloned gene for producing same
US6261800B1 (en) 1989-05-05 2001-07-17 Genentech, Inc. Luteinizing hormone/choriogonadotropin (LH/CG) receptor
EP1199361A3 (en) 1989-05-05 2004-03-10 Genentech Inc. Glycoprotein hormone receptor molecules. Their uses
US5744348A (en) 1989-09-08 1998-04-28 New England Medical Center Hospitals, Inc. TSH receptor
US5614363A (en) 1990-01-25 1997-03-25 New England Medical Center Hospitals, Inc. TSH receptor
EP0433509B1 (en) * 1989-12-14 1996-11-13 B.R.A.H.M.S Diagnostica GmbH Polypeptides having thyrotropin receptor activity, nucleic acid sequences coding for such receptors and polypeptides, and applications of these polypeptides
EP0506890A4 (en) 1989-12-20 1993-06-30 Nichols Institute Diagnostics Recombinant thyrotropin receptor
JPH04149197A (ja) 1990-10-12 1992-05-22 Tanabe Seiyaku Co Ltd 新規ペプチド
EP0482598A3 (en) 1990-10-24 1993-05-19 Ishihara Sangyo Kaisha, Ltd. Peptide analog of human tsh receptor affective against autoimmune hyperthyroidism
US5578496A (en) 1991-12-19 1996-11-26 Board Of Regents, Baylor College Of Medicine Detection of autoantibodies associated with the disease myasthenia gravis
JPH07506810A (ja) 1992-02-10 1995-07-27 デューク・ユニバーシティ 自己抗原である病原性のｔ細胞エピトープおよびｂ細胞エピトープに対する寛容性を誘導するための合成ペプチドの使用
US5705400A (en) 1992-03-07 1998-01-06 Rsr Limited Assay for adrenal autoantigen
US5195860A (en) 1992-07-20 1993-03-23 Trw Inc. Push-on type fastener for automatic feed and installation equipment
JPH06220089A (ja) 1993-01-27 1994-08-09 Ishihara Sangyo Kaisha Ltd ペプチド又はその塩並びにそれらを含有する自己免疫性甲状腺疾患の診断薬又は治療薬
EP0683396A1 (en) 1993-02-04 1995-11-22 Sumitomo Pharmaceuticals Company, Limited Method of assaying specific antibody
DE4328070C1 (de) 1993-08-20 1994-11-24 Henning Berlin Gmbh Verfahren zur Bestimmung eines Analyten in einem Volumen einer flüssigen Probe sowie seine Anwendung zur Bestimmung von anti-TSH-Rezeptor-Autoantikörpern in einem Patientenserum
JPH0789991A (ja) 1993-09-28 1995-04-04 Mitsubishi Chem Corp 新規なポリペプチドおよびそれを用いるｔｓｈ受容体抗体の測定法
EP0719858A3 (en) 1994-12-27 1997-12-29 Tosoh Corporation Myeloma cell line expressing recombinant human thyroid stimulating hormone receptor
DE19505266C1 (de) 1995-02-16 1996-10-02 Brahms Diagnostica Gmbh Verwendung von polyklonalen humanen anti-hTg-Autoantikörpern als Reagenz für die klinische Diagnostik von Schilddrüsen-Autoimmunerkrankungen sowie Reagenziensatz für eine Bestimmung von anti-hTg-Autoantikörpern in Patientenseren
DE19522171C1 (de) 1995-06-19 1996-08-22 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Anti-TSH-Rezeptor-Autoantikörpern
US5723343A (en) 1995-08-28 1998-03-03 University Of Florida Autoantibodies in patients with acquired hypoparathyroidism and assay method therefor
DE59712916D1 (de) 1996-11-06 2008-03-20 Bosch Gmbh Robert Elektrochemischer messfühler
US5734464A (en) 1996-11-06 1998-03-31 Cobe Laboratories, Inc. Red blood cell spillover detection technique
DE19728991A1 (de) 1996-11-06 1999-02-11 Brahms Diagnostica Gmbh Rezeptorbindungsassay, für den Rezeptorbindungsassay geeigneter rekombinanter Fusionsrezeptor, Vektor zu dessen Herstellung sowie Reagenziensatz für die Durchführung des Rezeptorbindungsassays
DE19651093C2 (de) * 1996-12-09 1999-06-10 Brahms Diagnostica Gmbh Rezeptorbindungsassay zum Nachweis von TSH-Rezeptor-Autoantikörpern sowie Reagenziensatz für die Durchführung eines solchen Rezeptorbindungsassays
IL123888A0 (en) 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
GB9909661D0 (en) * 1998-06-06 1999-06-23 Rsr Ltd Assays for TSH receptor autoantibodies
WO2000005345A1 (en) * 1998-07-21 2000-02-03 Basil Rapoport Human thyrotropin receptor compositions and use thereof
GB9823397D0 (en) * 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
JP4427878B2 (ja) * 1999-08-20 2010-03-10 味の素株式会社 析出を伴う発酵法によるｌ−グルタミン酸の製造法
EP1078986B1 (en) * 1999-08-24 2007-02-28 Tosoh Corporation Secretory thyroid stimulating hormone receptor (TSHR), and method for assaying anti-TSHR antibody using the same
EP1224473B1 (de) 1999-10-12 2005-08-17 Ulrich Loos Verfahren zur bestimmung von autoantikörpern gegen den tsh-rezeptor
WO2001044300A2 (en) 1999-12-13 2001-06-21 Cambridge Antibody Technology Limited Brain specific binding members
WO2001063296A2 (de) 2000-02-21 2001-08-30 Milo Gmbh Verfahren zur differentialdiagnostischen bestimmung von gegen den tsh-rezeptor gebildeten autoantikörpern in einer serum- oder plasmaprobe eines patienten
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
CA2409991A1 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
DE10126968A1 (de) 2001-06-01 2002-12-12 Ivoclar Vivadent Ag Farbstoffzusammensetzung zum individuellen Einfärben von Prothesenkunststoffen
ES2736165T3 (es) 2001-08-23 2019-12-26 Rsr Ltd Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas
WO2004050708A2 (en) 2002-11-29 2004-06-17 Rsr Limited Antibody for the thyrotropin receptor and uses thereof
PL2121758T3 (pl) * 2007-02-15 2015-02-27 R S R Ltd Ludzkie przeciwciała monoklonalne przeciwko receptorowi tyreotropiny, które działają jako antagoniści
JP5784504B2 (ja) * 2008-12-24 2015-09-24 アールエスアール リミテッド ヒト抗ｔｓｈｒ抗体

Also Published As

Publication number Publication date
EP2383290B1 (en) 2019-05-08
CN103224562A (zh) 2013-07-31
US20090203036A1 (en) 2009-08-13
ES2736165T3 (es) 2019-12-26
US20050118638A1 (en) 2005-06-02
EP2383291B1 (en) 2019-04-17
CN103224562B (zh) 2017-09-08
ES2466377T3 (es) 2014-06-10
CN1622958A (zh) 2005-06-01
US8309693B2 (en) 2012-11-13
US20130089561A1 (en) 2013-04-11
WO2003018632A3 (en) 2004-06-17
US20090202438A1 (en) 2009-08-13
JP5576072B2 (ja) 2014-08-20
EP1456234B1 (en) 2014-04-09
CN1622958B (zh) 2013-04-03
EP2383290A2 (en) 2011-11-02
US9751940B2 (en) 2017-09-05
JP2009278998A (ja) 2009-12-03
US8298769B2 (en) 2012-10-30
ES2732276T3 (es) 2019-11-21
CN101799476B (zh) 2013-01-02
WO2003018632A2 (en) 2003-03-06
US8298771B2 (en) 2012-10-30
CN101799476A (zh) 2010-08-11
EP2383291A3 (en) 2013-02-13
EP1456234A2 (en) 2004-09-15
EP2383290A3 (en) 2012-10-10
EP2383291A2 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
JP5576072B2 (ja) チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体
JP2009278998A5 (https=)
US5691448A (en) Reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
US8298770B2 (en) Methods, kits, and antibodies for detecting parathyroid hormone
US7649084B2 (en) Recombinant glycoproteins related to feline thyrotropin
US20080064858A9 (en) Binding partners for the thyrotropin receptor and uses thereof
WO1994012529A9 (en) Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
KR20220122467A (ko) 사스-코로나바이러스-2에 특이적으로 결합하는 항체 및 그의 용도
JPH02479A (ja) ｓｎＲＮＰ−Ａ抗原及びそのフラグメント
JP4980901B2 (ja) 新規なモノクローナル甲状腺刺激または阻害抗体、その可変領域に相当するペプチド配列、ならびに診断用医薬、予防用医薬および治療用医薬におけるそれらの使用
JP4059404B2 (ja) 甲状腺機能を刺激する活性を持つ抗体
Kosugi et al. Epitope analysis of the thyrotropin receptor, 1997
CN118525034A (zh) 犬白介素-31受体αI的犬源化抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080729

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081217

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090814

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090819

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20090911